Results from UALCAN and GEPIA indicated that the mRNA levels of OAS1, OAS2, OAS3, and OASL were markedly higher (p-value < 0.05) in breast cancer samples compared to normal samples (Fig. 3A-B), aligning with the outcomes observed in cell lines. This evidence concerns the gene OAS2 and breast carcinoma.